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Abstract: It is often difficult to determine whether a patient may best benefit by augmenting 
their current medication or switching them to another. This post-hoc analysis compares patients’ 
clinical and functional profiles at the time their antipsychotic medications were either switched 
or augmented. Adult outpatients receiving oral antipsychotic treatment for schizophrenia were 
assessed during a 12-month international observational study. Clinical and functional measures 
were assessed at the time of first treatment switch/augmentation (0–14 days prior) and compared 
between Switched and Augmented patient groups. Due to low numbers of patients providing 
such data, interpretations are based on effect sizes. Data at the time of change were available for 
87 patients: 53 Switched and 34 Augmented. Inadequate response was the primary reason for 
treatment change in both groups, whereas lack of adherence was more prevalent in the Switched 
group (26.4% vs 8.8%). Changes in clinical severity from study initiation to medication change 
were similar, as indicated by Clinical Global Impressions–Severity scores. However, physical and 
mental component scores of the 12-item Short-Form Health Survey improved in the Augmented 
group, but worsened in the Switched group. These findings suggest that the patient’s worsening 
or lack of meaningful improvement prompts clinicians to switch antipsychotic medications, 
whereas when patients show some improvement, clinicians may be more likely to try bolstering 
the improvements through augmentation. Current findings are consistent with physicians’ stated 
reasons for switching versus augmenting antipsychotics in the treatment of schizophrenia. 
Confirmation of these findings requires further research.
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Introduction
Treatment optimization for patients with schizophrenia remains a challenge, considering 
that approximately one-third of patients are resistant to a particular treatment,1 and as 
many as half of all patients in a given year will have their antipsychotic medications 
switched.2 Although current treatment guidelines3–5 recommend monotherapy 
as a first-line strategy, switching to another medication is recommended for patients 
experiencing no relief of symptoms. Furthermore, if multiple attempts at monotherapy 
fail, augmentation – the use of a combination of agents – is suggested. In usual care, 
antipsychotic medication-use patterns often do not match treatment guidelines, and the 
drivers of antipsychotic polypharmacy in the treatment of schizophrenia are not well 
understood. Surveys indicate that physicians choose medication augmentation to bolster 
a patient’s partial or suboptimal improvements, particularly of positive symptoms, 
whereas lack of response or clinical worsening leads to the decision to switch the 
patient to another antipsychotic medication.6–8 To the best of our knowledge, there are 
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
113
ORIgINAL RESEARCH
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/NDT.S30268Neuropsychiatric Disease and Treatment 2012:8
no publications of “real world” studies in which the clinical or 
functional profiles of patients with schizophrenia have been 
assessed at the time their antipsychotic medications were 
switched or augmented. Moreover, there are no prospective 
studies in usual care in which treating physicians were queried 
about their reasons for switching or augmenting medications 
in the treatment of patients with schizophrenia.
The opportunity to expand our understanding of 
what drives the decision to switch or augment a patient’s 
antipsychotic medication has become available recently in a 
12-month, prospective, observational study of schizophrenia 
in usual practice settings.9 This study assessed the clinical and 
functional status of patients at the time of oral antipsychotic 
medication switch/augmentation, as well as physicians’ 
reasons for making these changes, at the time the treatment 
changes took place. The objectives of the current exploratory, 
post-hoc analysis, which was based on data from that study, 
were twofold. The primary objective was to compare the 
clinical and functional profiles of patients undergoing 
treatment switching or augmentation by examining (A) 
scores at study entry, (B) scores at the time of their first 
switch/augmentation following study initiation, and (C) 
change scores from study entry to the time of their first 
switch/augmentation. In addition, this study’s secondary 
objective was to compare reasons for the switching versus 
augmentation, as reported by the patients’ treating physicians 
at the time these changes were made in patients’ medication 
regimens.
Methods
We used data from an international, 12-month, prospec-
tive, observational, noninterventional study (study F1D-
AY-B033),9 conducted in Australia, Mexico, Romania, 
and Taiwan, which examined time to all-cause treatment 
discontinuation in adult outpatients diagnosed with 
schizophrenia (Diagnostic and Statistical Manual of 
Mental Disorders, fourth edition, or fourth edition, text 
revision). Inclusion criteria included a need to switch from 
ongoing antipsychotic treatment to another antipsychotic 
due to a risk of medication nonadherence per treating 
clinicians’ perceptions and an experience of at least two 
previous episodes of clinical worsening in the preceding 
24 months that required hospitalization or an increased 
level of care. The time of this initial switch constituted 
the time of entry to the study. This analysis focuses on 
those patients who were switched at study entry to an oral 
antipsychotic. Patients were excluded from the study if they 
were considered by their clinician to be treatment-resistant. 
After procedures and possible side effects were explained to 
them, all participating patients provided written consent to 
participate in the study, which was conducted in accordance 
with the Declaration of Helsinki and all applicable local 
laws and regulations.
In addition to examination of patient demographics 
and illness characteristics at study entry, assessments were 
made of the number of patients who were hospitalized 
in the 24 months prior to study initiation, and previous 
antipsychotic use was noted. Physicians’ reported reasons for 
medication switch/augmentation after study initiation were 
documented, and times to switch/augmentation after study 
initiation and times to all-cause discontinuation from the 
study were recorded. Clinical and functional measures were 
assessed at study entry and at the time of the first treatment 
switch/augmentation (the most recent observation within the 
14 days preceding the change) after study entry. Changes 
in these measures from study entry to the first switch/
augmentation event after study initiation were calculated. 
Severity of patients’ illness was measured with the Clinical 
Global Impressions–Severity scale (CGI-S),10 with scores 
ranging from 1 = “normal/not at all ill” to 7 = “among the 
most extremely ill patients.” Patients’ functioning and well-
being were measured with the physical and mental component 
scores of the patient-rated, 12-item Short-Form Health Survey 
(SF-12),11 with scores standardized to a scale of 0 to 100, 
where higher scores represent better functioning. Health-
related quality of life was assessed with the utility index and 
health state scores of the patient-reported European Quality of 
Life-5-Dimensions scale (EQ-5D).12 Each dimension is rated 
from 1 = “better health state (no problems)” to 3 = “worst 
health state (confined to bed)” and transformed to a single 
utility index score scaled from 0 = death to 1 = perfect health. 
The health state score is scaled from 0 = “worst imaginable 
health state” to 100 = “best imaginable health state.” Patients’ 
attitudes towards the medication intake were assessed with 
the self-reported 10-item Drug Attitude Inventory (DAI-10),13 
with a range of −10 to +10, higher scores reflecting better 
attitudes. Patients’ insight into their illness was measured 
with the Scale to Assess Unawareness of Mental Disorder-
Abbreviated version (SUMD-A),14 a semistructured, 
nine-item, open interview with item scores ranging from 
1 = “aware” to 3 = “severely unaware.” The SUMD-A total 
score is computed from the total of all nine items, with a range 
of 1 to 27, higher scores indicating more awareness.
Differences at study entry between the Switched and 
Augmented patient groups were analyzed using descrip-
tive statistics. Time to first switch/augmentation after study 
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initiation and time to discontinuation from the study were 
calculated from the date of study entry until the date of 
the event. Patient data were censored from the analysis if 
the patient had completed the study, died, or was lost to 
follow-up. Results were analyzed using descriptive statis-
tics and, where appropriate, Kaplan–Meier15 estimates for 
the median. Comparison of assessment scores at the time 
of event (switching/augmentation) and analysis of changes 
from study entry to event were performed using ANOVA and 
examination of standardized mean-difference effect sizes 
(Cohen’s d).16 However, no adjustment was made because 
no differences were observed between groups at baseline, 
the sample sizes were small, and covariate information was 
missing.
Results
Study F1D-AY-B033 enrolled a total of 406 patients, of 
whom 363 patients were switched at study entry to another 
oral antipsychotic, and 43 were switched at study entry to a 
depot antipsychotic. Of the 363 patients switched to an oral 
antipsychotic at study entry, 87 experienced at least one 
subsequent treatment switch or augmentation and provided 
data within 14 days prior to that switch/augmentation event 
(53 Switched, 34 Augmented). Of the other 276 patients, 
207 completed the study, 29 discontinued, 36 were lost to 
follow-up and could not be classified (switched, augmented, 
stopped, or discontinued), and four stopped their medication 
during the observation period. Some of the 87 patients 
included in this analysis did not provide data for all of 
the measures assessed at the time of their first switch/
augmentation following study entry; thus, sample sizes varied 
from one measure to another.
Demographic, clinical, and functional characteristics 
at study entry of the included 87 patients did not differ 
significantly from the overall patient sample. Their mean 
age was approximately 37 years, males slightly outnumbered 
females, and mean CGI-S scores at study entry (Table 1) 
indicated moderate to marked illness severity. Mean 
SF-12 scores indicated levels of functioning approximately 
0.5 to 1.5 standard deviations below the overall population 
norm, while EQ-5D scores indicated an average-to-poor 
health-related quality of life. Scores on the SUMD-A 
suggested a moderate level of patients’ insight into their 
illness, while DAI-10 scores indicated moderately positive 
attitudes towards the medications being taken.
Patients’ clinical and functional status at the time of 
first treatment switch/augmentation suggested greater 
improvement in the Augmented group than the Switched 
group (Figure 1). Although CGI-S scores changed very 
little in either group, both SF-12 and EQ-5D scores showed 
that the Augmented patient group experienced a slight 
improvement in mean functioning and health-related quality 
of life, whereas Switched patients showed no change or 
a slight worsening. Effect sizes were small to medium, 
with the exception of the effect size associated with changes 
in the SF-12 physical component score, which was large (and 
the only measure associated with a statistically significant 
improvement, despite the very small sample sizes). The 
latter also indicated improvement in the Augmented group 
and a worsening in the Switched group. Drug attitudes, as 
indicated by DAI-10 scores, were essentially unchanged in 
the Augmented group but worsened in the Switched group, 
with a small effect size associated with the difference between 
patient groups. Similarly, patients’ insights into their illness, 
as measured by the SUMD-A, were essentially unchanged in 
the Augmented group but worsened in the Switched group, 
with a medium effect size associated with the difference 
between patient groups. In lieu of median Kaplan–Meier 
estimates, the median time to event (switch, augmentation, 
or stop) was slightly longer in the Switched group 
Table 1 Measures at study entry for patients whose antipsychotic 
medication was Switched (n = 53) or Augmented (n = 34) during 
the 12-month study period
Measure n Mean (SD)
CgI-S
  Switched 53 4.10 (1.02)
  Augmented 34 4.30 (0.99)
SF-12 PCS
  Switched 53 46.25 (9.89)
  Augmented 34 41.95 (9.58)
SF-12 MCS
  Switched 53 35.27 (10.17)
  Augmented 34 37.17 (10.80)
EQ-5D utility
  Switched 51 0.68 (0.22)
  Augmented 31 0.64 (0.29)
EQ-5D Health State
  Switched 53 62.15 (21.51)
  Augmented 34 53.97 (26.24)
SUMD-A
  Switched 47 12.81 (4.33)
  Augmented 30 12.27 (5.10)
DAI-10
  Switched 51 2.82 (4.80)
  Augmented 33 3.03 (4.48)
Abbreviations: CgI-S, Clinical global Impressions-Severity scale; DAI-10, 10-item 
Drug  Attitude  Inventory;  EQ-5D,  5-dimension  European  Quality  of  Life  scale;   
MCS,  mental  health  component  score;  PCS,  physical  component  score;  SF-12, 
12-item  Short-Form  Health  Survey;  SD,  standard  deviation;  SUMD-A,  Scale  to 
Assess Unawareness of Mental Disorder-Abbreviated version.
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Figure 1 Effect sizes and changes from study entry to time of first switch or augmentation among patients experiencing a switch to (gray bars), or augmentation with (black 
bars), another oral antipsychotic following study initiation: (A) illness severity, as measured by the CgI-S, (B) functioning and well-being, as measured by the SF-12 physical 
(left) and mental component score (right), (C) quality of life, as measured by the EQ-5D utility index (left) and health state score (right), and (D) attitude towards medication 
intake and insight into illness, as measured by the SUMD-A (left) and DAI-10 (right), respectively. 
Notes: P = 0.01, difference between mean SF-12 PCS change scores for Switched and Augmented groups. All other measures were not statistically significant.
Abbreviations:  CgI-S,  Clinical  global  Impressions-Severity  scale;  DAI-10,  10-item  Drug  Attitude  Inventory;  EQ-5D,  5-dimension  European  Quality  of  Life  scale; 
MCS, mental health component score; ES, effect size for Augmented patient group, relative to Switched patient group, on change scores from study entry to time of first 
switch/augmentation event; PCS, physical component score; SF-12, 12-item Short-Form Health Survey; SD, standard deviation; SUMD-A, Scale to Assess Unawareness of 
Mental Disorder-Abbreviated version. 
(Switched: median = 5.5 months, minimum to maximum = 0 
to 12.8 months, n = 53; Augmented: median = 3.6 months, 
minimum to maximum = 0 to 10.7 months, n = 34). The 
median time to all-cause study discontinuation (dropout) 
was similar for the two groups (Switched: median 
12.2 months, minimum to maximum = 2.1 to 14.5 months, 
n = 53; Augmented: median = 12.3 months, minimum to 
maximum = 3.1 to 13.9 months, n = 34).
Reasons physicians’ reported for switching or augmenting   
their patients’ medications were generally not appreciably 
different between the two patient groups, with inadequate 
response being the leading reason in both groups (Switched: 
18 of 53, or 34.0%; Augmented: 14 of 34, or 41.2%). 
However, lack of adherence was somewhat more frequently 
observed in the Switched group, nearly attaining statistical 
significance (Switched: 14 of 53, or 26.4%; Augmented: 
three of 34, or 8.8%). Lack of tolerance was a less common 
reason for treatment change and was not different between 
patient groups (Switched: four of 53, or 7.5%; Augmented: 
three of 34, or 8.8%).
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Discussion
This study offers, for the first time, empirical corroboration 
of previous reports that physicians tend to switch a 
patient’s antipsychotic medication when there is lack of 
improvement,17,18 whereas they opt for augmentation in an 
attempt to consolidate clinical gains and optimize responses 
to medication.1,6 Patients in this analysis who underwent 
either a switch or an augmentation of their antipsychotic 
medication did not differ at the outset of the study. 
However, patients whose medications were switched after 
study entry had been worsening during the period leading 
up to the treatment change on most clinical and functional 
outcome measures, whereas patients whose medications 
were augmented had been showing some improvement. 
Interestingly, the primary reason for the treatment change, 
as reported by the treating physicians, was essentially the 
same for the two groups: lack of efficacy. This is consistent 
with the reasons for switching or augmentation that have 
been reported in a large systematic review of longitudinal 
antipsychotic prescriptions for up to 2 years.19 That study 
also revealed that nearly half of all patients who were 
switched to another antipsychotic were likely to have 
been underdosed, while patients whose antipsychotic was 
augmented by another had frequently undergone the change 
before having been tested, in the opinion of the investigators, 
with an adequate number of alternative antipsychotic 
medications in monotherapy. Patients requiring a treatment 
switch in our study were more likely to be reported as 
nonadherent. This in itself is a risk factor for treatment 
failure,20,21 poorer clinical and functional outcomes,20,22,23 and 
increased risk of hospitalization.22,23 By contrast, medication 
intolerability was a far less common reason for treatment 
change. These findings appear consistent with prior research 
showing that the lack of efficacy of a medication, rather than 
its intolerability, is the most frequent cause of treatment 
discontinuation.24
The current findings highlight the still unmet treatment 
needs of patients with schizophrenia – the need for a more 
effective and well-tolerated medication. As potential treat-
ments with different mechanisms of action continue to be 
investigated, it remains important to characterize reasons 
for switching versus augmentation and to develop evidence-
based guidance for clinicians that defines parameters for 
clinicians related to switching medications versus augmen-
tation with another agent.
Several limitations to this study bear mention. The most 
obvious limitation was its small sample sizes, which limited 
our ability to use statistical analyses to interpret the findings. 
Moreover, as this was a naturalistic study, patients were not 
randomly assigned to treatment. As a result, we were required 
to rely primarily on descriptive statistics and use effect sizes 
to estimate the relevance of the observed patient group 
differences. No adjustment was made for multiplicity of 
observations. Moreover, while lack of efficacy was revealed 
to be the major driver of the decision to change patients’ 
treatments in the case of both switching and augmenta-
tion, no   information was available regarding which specific 
  symptom or symptoms were of greatest concern to   physicians 
during either situation. Related to this is the finding that 
patients characterized by both a switch and an   augmentation 
were noted by their physicians to have demonstrated an 
“inadequate response.” However, this may have been driven 
by the limited options available to choose from in this study 
(for example, “inadequate response,” “intolerance to drug,” or 
“upon patient’s request”). If the clinicians had been   provided 
more refined response options, the differences between the 
Switched and Augmented groups might have been more 
accurately captured (that is, the Switched group had truly 
inadequate responses, whereas the Augmented group merely 
had suboptimal responses). Another limitation is the study’s 
inability to identify the cases in which augmentation of the 
current antipsychotic was actually a manifestation of an 
ongoing cross-titration with another antipsychotic (that is, a 
planned switch), which was aborted by the physician due to 
temporary or sustained improvement in the patient’s clinical 
or functional status.1
Conclusion
This post-hoc and preliminary analysis suggests that 
clinicians tend to switch a patient’s antipsychotic medication 
when symptoms worsen or show a lack of meaningful 
improvement, whereas they appear more likely to augment 
with another antipsychotic medication when the patient 
shows some improvement. However, this conclusion must 
be considered preliminary due to the study’s limitations. 
Confirmation will require further research.
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